Evidence map›Paper›PMID 41221043›Full record

ArticleFrontiers in pharmacology2025

Comparative

Ali Khamesipour, Minoo Tasbihi, Akram Mir Amin Mohammadi, Jodie Dixon, David J Clark, Henry M Staines, Sanjeev Krishna, Vanessa Yardley, Simon L Croft, Neal Alexander and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ali KhamesipourCenter for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
Minoo TasbihiCenter for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
Akram Mir Amin MohammadiCenter for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
Jodie DixonYork Biomedical Research Institute, Skin Research Centre, Hull York Medical School, University of York, York, United Kingdom.
David J ClarkInstitute for Infection and Immunity, City St George's University of London, London, United Kingdom.
Henry M StainesInstitute for Infection and Immunity, City St George's University of London, London, United Kingdom.
Sanjeev KrishnaInstitute for Infection and Immunity, City St George's University of London, London, United Kingdom.
Vanessa YardleyDepartment of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Simon L CroftDepartment of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Neal AlexanderDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Katrien Van BocxlaerYork Biomedical Research Institute, Skin Research Centre, Hull York Medical School, University of York, York, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous leishmaniasis (CL) is a neglected tropical disease caused by protozoan parasites of the genus

Indexed as

clinical isolatescutaneous leishmaniasisdose responsemiltefosineoleylphosphocholine

Identifiers

PMID41221043
PMCPMC12598013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.